9 5 7 4 9
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.3 Breast Cancer (Dove Med Press)
- 3.4 Clin Epidemiol
- 2.5 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.5 Clin Interv Aging
- 4.7 Drug Des Dev Ther
- 2.7 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.5 Int J Women's Health
- 2.5 Neuropsych Dis Treat
- 2.7 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.3 Ther Clin Risk Manag
- 2.5 J Pain Res
- 2.8 Diabet Metab Synd Ob
- 2.8 Psychol Res Behav Ma
- 3.0 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.7 Risk Manag Healthc Policy
- 4.2 J Inflamm Res
- 2.1 Int J Gen Med
- 4.2 J Hepatocell Carcinoma
- 3.7 J Asthma Allergy
- 1.9 Clin Cosmet Investig Dermatol
- 2.7 J Multidiscip Healthc
已发表论文
在采用贝伐珠单抗 (Bevacizumab) 治疗的非小细胞肺癌 (NSCLC) 患者中高血压的发病率和风险 ：对随机对照试验的一项综合分析
Authors Chen J, Lu Y, Zheng Y
Received 24 April 2015
Accepted for publication 7 July 2015
Published 18 August 2015 Volume 2015:9 Pages 4751—4760
DOI http://dx.doi.org/10.2147/DDDT.S87258
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Syed Nasir Abbas Bhukari
Peer reviewer comments 3
Editor who approved publication: Professor Shu-Feng Zhou
Aim: A study was conducted to determine the overall risk and incidence of hypertension with bevacizumab in non-small-cell lung cancer (NSCLC) patients.
Materials and methods: Electronic databases such as the Embase, PubMed, and Cochrane Library were searched for related trials. Statistical analyses were conducted to calculate the overall incidence rates, odds ratios (ORs), and 95% confidence intervals (CIs) by using either random-effect or fixed-effect models depending on the heterogeneity.
Results: A total of 3,155 subjects from nine studies were included. The overall incidences of all-grade and high-grade hypertension in NSCLC patients were 19.55% (95% CI 10.17%–34.3%) and 6.95% (95% CI 5.81%–8.30%). Bevacizumab use was associated with a significantly increased risk in all-grade hypertension (OR 8.07, 95% CI 3.87–16.85; P =0.0002) and high-grade hypertension (OR 5.93, 95% CI 3.41–10.32; P <0.0001). No evidence of publication bias was determined for the ORs of hypertension in our meta-analysis.
Conclusion: Bevacizumab is associated with a significantly increased risk of hypertension development in NSCLC patients. Early monitoring and effective management of hypertension might be important steps for the safe use of this drug.
Keywords: non-small-cell lung cancer, bevacizumab, hypertension, meta-analysis
Materials and methods: Electronic databases such as the Embase, PubMed, and Cochrane Library were searched for related trials. Statistical analyses were conducted to calculate the overall incidence rates, odds ratios (ORs), and 95% confidence intervals (CIs) by using either random-effect or fixed-effect models depending on the heterogeneity.
Results: A total of 3,155 subjects from nine studies were included. The overall incidences of all-grade and high-grade hypertension in NSCLC patients were 19.55% (95% CI 10.17%–34.3%) and 6.95% (95% CI 5.81%–8.30%). Bevacizumab use was associated with a significantly increased risk in all-grade hypertension (OR 8.07, 95% CI 3.87–16.85; P =0.0002) and high-grade hypertension (OR 5.93, 95% CI 3.41–10.32; P <0.0001). No evidence of publication bias was determined for the ORs of hypertension in our meta-analysis.
Conclusion: Bevacizumab is associated with a significantly increased risk of hypertension development in NSCLC patients. Early monitoring and effective management of hypertension might be important steps for the safe use of this drug.
Keywords: non-small-cell lung cancer, bevacizumab, hypertension, meta-analysis
